{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:46:59Z","timestamp":1772261219479,"version":"3.50.1"},"reference-count":24,"publisher":"National Center for Global Health and Medicine (JST)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2026,2,25]]},"DOI":"10.35772\/ghm.2025.01134","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:09:12Z","timestamp":1771366152000},"page":"33-38","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the link between Japanese Anticholinergic Risk Scale and laxative prescription in older adults: A cross-sectional study of 9,838 patients using dispensing claims from community pharmacies"],"prefix":"10.35772","volume":"8","author":[{"given":"Wataru","family":"Takahashi","sequence":"first","affiliation":[{"name":"Specialized Education Department, Education and Training Division, Qol Co., Ltd., Tokyo, Japan."},{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Specialized Education Department, Education and Training Division, Qol Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reika","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019; 67:674-694.","DOI":"10.1111\/jgs.15767"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr. 2015; 15:31.","DOI":"10.1186\/s12877-015-0029-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013; 144:218-238.","DOI":"10.1053\/j.gastro.2012.10.028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: Impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010; 31:938-949.","DOI":"10.1111\/j.1365-2036.2010.04273.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil. 2005; 17:643-653.","DOI":"10.1111\/j.1365-2982.2005.00675.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rodr\u00edguez-Ramallo H, B\u00e1ez-Guti\u00e9rrez N, Prado-Mel E, Alfaro-Lara ER, Santos-Ramos B, S\u00e1nchez-Fidalgo S. Association between anticholinergic burden and constipation: A systematic review. Healthcare (Basel). 2021; 9:581.","DOI":"10.3390\/healthcare9050581"},{"key":"7","unstructured":"7. Japanese Society of Geriatric Pharmacy Working Group. Japanese Anticholinergic Risk Scale (JARS), 2nd edition. <i>https:\/\/www.jsgp.or.jp\/wp\/wp-content\/uploads\/2024\/05\/anticholinergic-risk-scale.pdf<\/i> (accessed May 17, 2024). (in Japanese)"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005; 58:323-337.","DOI":"10.1016\/j.jclinepi.2004.10.012"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: Standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010; 20:413-419.","DOI":"10.2188\/jea.JE20090066"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takeuchi M, Nakano S, Tanaka-Mizuno S, Nishiyama C, Doi Y, Arai M, Fujii Y, Matsunaga T, Kawakami K. Adherence and concomitant medication use among patients on warfarin therapy: Insight from a large pharmacy dispensing database in Japan. Biol Pharm Bull. 2019; 42:389-393.","DOI":"10.1248\/bpb.b18-00576"},{"key":"11","unstructured":"11. Ministry of Health, Labour and Welfare. Overview of the FY2016 revisions of prescription drug dispensing fees and related medical service fees. <i>https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-12400000-Hokenkyoku\/0000116338.pdf<\/i> (accessed October 20, 2025). (in Japanese)"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iketani R, Konomura K. Utility of the family pharmacist system: A retrospective cohort study using claims data. Japanese Journal of Pharmaceutical Health Care and Sciences. 2021; 47:453-463. (in Japanese)","DOI":"10.5649\/jjphcs.47.453"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Weng MC, Tsai CF, Sheu KL, Lee YT, Lee HC, Tzeng SL, Ueng KC, Chen CC, Chen SC. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. QJM. 2013; 106:1009-1015.","DOI":"10.1093\/qjmed\/hct141"},{"key":"14","unstructured":"14. Goto N, Takimoto M, Shido S, Sato K, Nakamura T. Investigation of polypharmacy using a community pharmacy claims database in Japan. Journal of Pharmaceutical Health Care and Sciences. 2023; 49:37-45. (in Japanese)"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17:230.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003; 158:915-920.","DOI":"10.1093\/aje\/kwg231"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yang N, Wu Q, Xu F, Zhang X. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: A network meta-analysis. J Int Med Res. 2021; 49:3000605211042994.","DOI":"10.1177\/03000605211042994"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kan Y, Doi M, Uesawa Y. Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: A retrospective pharmacovigilance study. J Pharm Health Care Sci. 2025; 11:8.","DOI":"10.1186\/s40780-025-00413-w"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aball\u00e9a S, Nazir J, Chapple C. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis. Eur Urol. 2018; 74:324-333.","DOI":"10.1016\/j.eururo.2018.03.020"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhang L, Cai N, Mo L, Tian X, Liu H, Yu B. Global prevalence of overactive bladder: A systematic review and meta-analysis. Int Urogynecol J. 2025; 36:1547-1566.","DOI":"10.1007\/s00192-024-06029-2"},{"key":"21","unstructured":"21. Pratt LA, Brody DJ, Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011\u20132014. NCHS Data Brief. 2017; 283:1-8."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:1582-1591; quiz 1581, 1592.","DOI":"10.1038\/ajg.2011.164"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: A systematic review. BMC Gastroenterol. 2008; 8:5.","DOI":"10.1186\/1471-230X-8-5"},{"key":"24","unstructured":"24. Ministry of Health, Labour and Welfare. NDB Open Data, 10th release. <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177221_00016.html<\/i> (accessed October 20, 2025). (in Japanese)"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/8\/1\/8_2025.01134\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:20:57Z","timestamp":1772252457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/8\/1\/8_2025.01134\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2025.01134","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"2025.01134"}}